Transport Characteristics of a Beta Sheet Breaker Peptide Across Excised Bovine Nasal Mucosa

ABSTRACT The purpose of the present study was to investigate the permeation characteristics of the beta sheet breaker peptide AS 602704 (BSB) on excised bovine nasal mucosa using an Ussing chamber model. The influence of various absorption enhancers such as sodium cholate, sodium dodecyl sulfate (SDS), cetrimidum, sodium caprate, Na2EDTA, polycarbophil (PCP), the thiomer conjugate polycarbophil-cysteine (PCP-Cys), and poly-l-arginine (poly-l-arg; 100 kDa) was evaluated. Additionally, the influence of temperature and pH on the transport rate as well as the stability of the peptide drug against enzymatic degradation were investigated in vitro. The effective permeability coefficient (Peff) of BSB in Krebs-Ringer-buffer (KRB) pH 7.4 was (1.89 ± 0.44)* 10−5, while in the presence of sodium caprate (0.5%) a Peff of (9.58 ± 1.82)*10−5 was achieved. Rank order of enhancement ratio was sodium caprate > SDS > sodium cholate > Na2EDTA > poly-l-arg = PCP-Cys. In case of cetrimidum and PCP even a decrease in the absorption of BSB was determined. Na2EDTA reduced the enzymatic degradation of BSB when exposed to a nasal tissue homogenate by more than the half. An increased lipophilicity of BSB because of a more acidic milieu (pH 5.5) did not lead to an increased transcellular transport. Permeation studies carried out at 4°C compared to 37°C demonstrated a temperature dependent permeation behaviour suggesting an additional active carrier mediated transport. The results obtained within these studies should facilitate the development of a nasal delivery system for AS 602704 for the treatment of Alzheimer's disease.

[1]  A. Bernkop‐Schnürch,et al.  Thiomers in noninvasive polypeptide delivery: in vitro and in vivo characterization of a polycarbophil-cysteine/glutathione gel formulation for human growth hormone. , 2004, Journal of pharmaceutical sciences.

[2]  H. Feldman,et al.  Treatment of Alzheimer's disease; current status and new perspectives , 2003, The Lancet Neurology.

[3]  S. M. Robinson,et al.  Pharmacological Profiles of Peptide Drug Candidates for the Treatment of Alzheimer's Disease* , 2003, The Journal of Biological Chemistry.

[4]  J. Karlawish,et al.  Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies , 2003, Annals of Internal Medicine.

[5]  L. Illum Nasal drug delivery--possibilities, problems and solutions. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[6]  M. Citron,et al.  Alzheimer's disease: treatments in discovery and development , 2002, Nature Neuroscience.

[7]  H. Natsume,et al.  Analysis of transient and reversible effects of poly-L-arginine on the in vivo nasal absorption of FITC-dextran in rats. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[8]  C. Soto,et al.  Beta‐sheet breaker strategy for the treatment of Alzheimer's disease , 2002 .

[9]  Claudio Soto,et al.  Reduction of amyloid load and cerebral damage in transgenic mouse model of Alzheimer's disease by treatment with a β‐sheet breaker peptide , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  A. Bernkop‐Schnürch,et al.  The Role of Glutathione in the Permeation Enhancing Effect of Thiolated Polymers , 2002, Pharmaceutical Research.

[11]  W. Rubas,et al.  Validation of excised bovine nasal mucosa as in vitro model to study drug transport and metabolic pathways in nasal epithelium. , 2000, Journal of pharmaceutical sciences.

[12]  H. Natsume,et al.  Screening of cationic compounds as an absorption enhancer for nasal drug delivery. , 1999, International journal of pharmaceutics.

[13]  C. Soto,et al.  Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. , 1999, Molecular medicine today.

[14]  A. Bernkop‐Schnürch,et al.  Polymers with Thiol Groups: A New Generation of Mucoadhesive Polymers? , 1999, Pharmaceutical Research.

[15]  H. Merkle,et al.  Permeation and Pathways of Human Calcitonin (hCT) Across Excised Bovine Nasal Mucosa , 1998, Peptides.

[16]  Romeo,et al.  Effects of physicochemical properties and other factors on systemic nasal drug delivery. , 1998, Advanced drug delivery reviews.

[17]  Hussain,et al.  Intranasal drug delivery. , 1998, Advanced drug delivery reviews.

[18]  Romeo,et al.  Optimization of systemic nasal drug delivery with pharmaceutical excipients. , 1998, Advanced drug delivery reviews.

[19]  Peter,et al.  In vitro cell models to study nasal mucosal permeability and metabolism. , 1998, Advanced drug delivery reviews.

[20]  H. Merkle,et al.  Transport and Metabolic Pathway of Thymocartin (TP4) in Excised Bovine Nasal Mucosa , 1996, The Journal of pharmacy and pharmacology.

[21]  Lisbeth Illum,et al.  Absorption Enhancers for Nasal Drug Delivery , 2003, Clinical pharmacokinetics.

[22]  B. Permanne,et al.  Are β-sheet breaker peptides dissolving the therapeutic problem of Alzheimer’s disease? , 2002 .